Thrombolysis for acute ischaemic stroke: current status and future perspectives
Alteplase is currently the only approved thrombolytic agent for treatment of acute ischaemic
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …
stroke, but interest is burgeoning in the development of new thrombolytic agents for systemic …
Canadian stroke best practice recommendations: acute stroke management, practice guidelines update, 2022
M Heran, P Lindsay, G Gubitz, A Yu… - Canadian Journal of …, 2024 - cambridge.org
The 2022 update of the Canadian Stroke Best Practice Recommendations (CSBPR) for
Acute Stroke Management, 7th edition, is a comprehensive summary of current evidence …
Acute Stroke Management, 7th edition, is a comprehensive summary of current evidence …
Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial
Background There is increasing interest in replacing alteplase with tenecteplase as the
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …
preferred thrombolytic treatment for patients with acute ischaemic stroke. We aimed to …
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
Background Thrombolytic agents, including tenecteplase, are generally used within 4.5
hours after the onset of stroke symptoms. Information on whether tenecteplase confers …
hours after the onset of stroke symptoms. Information on whether tenecteplase confers …
Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial
MB Roaldsen, A Eltoft, T Wilsgaard… - The Lancet …, 2023 - thelancet.com
Background Current evidence supports the use of intravenous thrombolysis with alteplase in
patients with wake-up stroke selected with MRI or perfusion imaging and is recommended in …
patients with wake-up stroke selected with MRI or perfusion imaging and is recommended in …
Piperacillin-tazobactam compared with cefoxitin as antimicrobial prophylaxis for pancreatoduodenectomy: a randomized clinical trial
Importance Despite improvements in perioperative mortality, the incidence of postoperative
surgical site infection (SSI) remains high after pancreatoduodenectomy. The effect of broad …
surgical site infection (SSI) remains high after pancreatoduodenectomy. The effect of broad …
Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke: the comparative effectiveness of routine tenecteplase vs …
Importance Symptomatic intracranial hemorrhage (sICH) is a serious complication of stroke
thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of …
thrombolytic therapy. Many stroke centers have adopted 0.25-mg/kg tenecteplase instead of …
[HTML][HTML] The vessel has been recanalized: now what?
When treating acute ischemic stroke patients in our daily clinical practice, we strive to
achieve recanalization of the occluded blood vessel as fast as possible using …
achieve recanalization of the occluded blood vessel as fast as possible using …
[HTML][HTML] Tenecteplase vs. alteplase for treatment of acute ischemic stroke: a systematic review and meta-analysis of randomized trials
Background and objectives Several randomized controlled trials (RCTs) have compared
tenecteplase to alteplase for treatment of acute ischemic stroke (AIS). Yet, there is no meta …
tenecteplase to alteplase for treatment of acute ischemic stroke (AIS). Yet, there is no meta …
Intravenous thrombolysis with tenecteplase for the treatment of acute ischemic stroke
Objective Intravenous thrombolysis (IVT) with tenecteplase has been associated with better
clinical outcomes in acute ischemic stroke (AIS) patients with confirmed large vessel …
clinical outcomes in acute ischemic stroke (AIS) patients with confirmed large vessel …